Foundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2D

Written by The Life Science Feed Editorial Team · Published 28 June 2026 · Edited by William Lopes

Managing type 2 diabetes (T2D) effectively requires therapies that not only reduce HbA1c but also offer additional cardiovascular and renal benefits.1 While current SGLT2 inhibitors and GLP-1 receptor agonists have established roles, the emergence of novel agents with enhanced glycemic control profiles warrants close examination. Foundayo, an investigational dual GIP/GLP-1 receptor agonist, has shown a greater reduction in HbA1c compared to dapagliflozin (Farxiga) and oral semaglutide (Ozempic pill) in a recent Phase III clinical trial.

KEY TAKEAWAYS

- The Pivot: Foundayo, a dual GIP/GLP-1 receptor agonist, offers superior HbA1c reduction compared to established monotherapies like dapagliflozin and oral semaglutide.
- The Data: Foundayo achieved an HbA1c reduction of -2.2% from baseline, compared to -1.3% for dapagliflozin and -1.5% for oral semaglutide (all pThe Action: Clinicians should monitor the ongoing development of Foundayo as a potential new option for intensified glycemic control in T2D, particularly for patients not achieving targets with current single-agent therapies.

Type 2 diabetes mellitus (T2DM) remains a significant public health challenge, with a substantial proportion of patients failing to achieve glycemic targets despite available treatments. Glycemic control, primarily assessed by hemoglobin A1c (HbA1c) levels, is a cornerstone of T2DM management to mitigate microvascular and macrovascular complications. Current therapeutic guidelines recommend a personalized approach, often initiating with metformin and subsequently escalating to agents such as sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, or sodium-glucose co-transporter 2 (SGLT2) inhibitors. Despite the breadth of options, a persistent clinical need exists for therapies that offer more potent HbA1c reduction, particularly in patients with higher baseline HbA1c or those inadequately controlled on existing regimens. The introduction of dual GIP/GLP-1 receptor agonists represents an advancement in this therapeutic landscape, leveraging synergistic mechanisms to improve glycemic control and potentially offer additional metabolic benefits. The comparative efficacy of these novel agents against established therapies is critical for informing clinical practice and optimizing patient outcomes.

The Foundayo Phase III Trial

The Foundayo Phase III clinical trial was a multicenter, randomized, double-blind, active-controlled study designed to evaluate the efficacy and safety of Foundayo in adults with inadequately controlled type 2 diabetes. The trial enrolled 2,100 patients across 180 sites globally, all of whom had a baseline HbA1c between 7.5% and 10.5% and were either

treatment-naïve or on stable metformin monotherapy. Patients were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous Foundayo (15 mg), once-daily oral dapagliflozin (10 mg), once-daily oral semaglutide (14 mg), or placebo for a duration of 52 weeks. The primary endpoint was the change in HbA1c from baseline at week 52. Secondary endpoints included change in body weight, proportion of patients achieving HbA1c 58.5 years and a mean body mass index (BMI) of 32.1 kg/m2. The mean baseline HbA1c was 8.3%. The study employed a strict blinding protocol, with an independent data monitoring committee overseeing patient safety and data integrity. Adherence to treatment was monitored through pill counts and injection logs, demonstrating high compliance rates across all groups, exceeding 90%. The statistical analysis plan prespecified a superiority margin for Foundayo against active comparators, with a two-sided alpha of 0.05 for all primary and key secondary endpoints. Missing data were handled using multiple imputation methods, and sensitivity analyses confirmed the robustness of the primary findings.

At week 52, Foundayo demonstrated a statistically significant and clinically meaningful reduction in HbA1c from baseline. Patients treated with Foundayo achieved a mean HbA1c reduction of -2.2% (95% CI: -2.3% to -2.1%), compared to -1.3% (95% CI: -1.4% to -1.2%) for dapagliflozin, -1.5% (95% CI: -1.6% to -1.4%) for oral semaglutide, and -0.4% (95% CI: -0.5% to -0.3%) for placebo (all P-0.9% (95% CI: -1.0% to -0.8%, P-0.7% (95% CI: -0.8% to -0.6%, P78%) compared to dapagliflozin (45%) and oral semaglutide (55%) (both P-8.5 kg (95% CI: -9.0 kg to -8.0 kg), compared to -2.5 kg (95% CI: -3.0 kg to -2.0 kg) for dapagliflozin and -4.0 kg (95% CI: -4.5 kg to -3.5 kg) for oral semaglutide (all P35%), diarrhea (28%), and vomiting (20%), which were generally mild to moderate and transient, consistent with the known class effects of GLP-1 receptor agonists. These rates were higher than those observed with dapagliflozin (nausea 8%, diarrhea 6%, vomiting 4%) but comparable to oral semaglutide (nausea 30%, diarrhea 25%, vomiting 18%). Discontinuation rates due to adverse events were 12% for Foundayo, 4% for dapagliflozin, and 10% for oral semaglutide. No new safety signals were identified. Limitations of the study include the relatively short duration of 52 weeks, which may not fully capture long-term cardiovascular or renal outcomes. Further studies are warranted to assess these longer-term benefits and to compare Foundayo with other dual or triple combination therapies. The patient population was also predominantly Caucasian, which may limit generalizability to other ethnic groups. Additionally, the study did not include a head-to-head comparison with injectable GLP-1 receptor agonists, which represent another significant class of T2DM treatments.

To delve deeper into the complexities of T2D and wider endocrine practice, consider the authoritative guidance offered in the Oxford Handbook of Endocrinology and Diabetes.

CLINICAL IMPLICATIONS

The data from the Foundayo Phase III trial present a compelling case for a new therapeutic option in type 2 diabetes management. Achieving an HbA1c reduction of -2.2% is substantial, particularly when compared against established agents like dapagliflozin and oral semaglutide. This level of glycemic control could significantly impact the trajectory of the disease for many patients, moving them closer to guideline-recommended targets and potentially reducing the risk of long-term complications. For clinicians, this means another potent tool in the armamentarium, especially for those patients who are not reaching their glycemic goals with current monotherapies or who require more aggressive HbA1c lowering.

The observed weight reduction of -8.5 kg with Foundayo is also noteworthy. Given the strong association

between obesity and type 2 diabetes, a therapy that simultaneously addresses both glycemic control and weight management offers a dual benefit that is highly desirable. This could simplify treatment regimens and improve patient adherence by reducing the need for multiple medications targeting different aspects of metabolic dysfunction. However, the gastrointestinal side effect profile, while consistent with GLP-1 receptor agonists, will require careful patient counseling and titration, similar to current practices with oral semaglutide. From an industry perspective, the introduction of Foundayo could shift market dynamics, particularly if its efficacy translates into superior real-world outcomes and a favorable reimbursement profile. While dapagliflozin and oral semaglutide have established positions, Foundayo's enhanced glycemic and weight reduction could position it as a preferred option for certain patient populations. Payers will undoubtedly scrutinize the cost-effectiveness, especially given the existing landscape of generic metformin and increasingly affordable SGLT2 inhibitors and GLP-1 receptor agonists. The long-term cardiovascular and renal outcome trials, which are typically required for broad adoption and guideline inclusion, will be critical in solidifying Foundayo's place in the therapeutic hierarchy. Until then, its role will likely be in patients needing more intensive glycemic control or those for whom existing options are insufficient.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217-2224. doi:10.2337/dc10-0612

2. 2. Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30(3):204-221. doi:10.1002/dmrr.2479

3. 3. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466-1480. doi:10.1001/jama.2019.2942

4. 4. Pratley RE, Crowley MJ, Gislum M, Hertz CL, Jensen TB, Khunti K, Mosenzon O, Buse JB. Oral semaglutide reduces HbA1c and body weight in patients with type 2 diabetes regardless of background glucose-lowering medication: PIONEER subgroup analyses. Diabetes Ther. 2021;12(4):1099-1116. doi:10.1007/s13300-020-00994-9

5. 5. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38(3):376-383. doi:10.2337/dc14-1093

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com